Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Diffusion-weighted MR imaging and MGMT methylation status in glioblastoma: a reappraisal of the role of preoperative quantitative ADC measurements.

Gupta A, Prager A, Young RJ, Shi W, Omuro AM, Graber JJ.

AJNR Am J Neuroradiol. 2013 Jan;34(1):E10-1. doi: 10.3174/ajnr.A3467. Epub 2012 Dec 28. No abstract available.

2.

Reply: To PMID 21330401.

Pope W.

AJNR Am J Neuroradiol. 2013 Jan;34(1):E12. No abstract available.

3.

Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.

Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF.

AJNR Am J Neuroradiol. 2011 May;32(5):882-9. doi: 10.3174/ajnr.A2385. Epub 2011 Feb 17.

4.

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J.

Radiology. 2009 Jul;252(1):182-9. doi: 10.1148/radiol.2521081534.

PMID:
19561256
5.

Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.

Romano A, Calabria LF, Tavanti F, Minniti G, Rossi-Espagnet MC, Coppola V, Pugliese S, Guida D, Francione G, Colonnese C, Fantozzi LM, Bozzao A.

Eur Radiol. 2013 Feb;23(2):513-20. doi: 10.1007/s00330-012-2601-4. Epub 2012 Aug 10.

PMID:
22875158
6.

Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.

Gerstner ER, Frosch MP, Batchelor TT.

J Clin Oncol. 2010 Feb 20;28(6):e91-3. doi: 10.1200/JCO.2009.25.0233. Epub 2009 Nov 23. No abstract available.

7.

Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab.

Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB.

Magn Reson Med. 2012 Jan;67(1):237-45. doi: 10.1002/mrm.23003. Epub 2011 Jun 23.

PMID:
21702063
8.

Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?

Rieger J, Bähr O, Ronellenfitsch MW, Steinbach J, Hattingen E.

J Clin Oncol. 2010 Sep 20;28(27):e477; author reply e478. doi: 10.1200/JCO.2010.29.2029. Epub 2010 Jun 28. No abstract available.

9.

Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.

Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundan S, Wen PY, Huang RY.

J Neurooncol. 2014 Aug;119(1):149-58. doi: 10.1007/s11060-014-1464-8. Epub 2014 May 8.

PMID:
24805151
10.

Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker.

Jain R, Scarpace LM, Ellika S, Torcuator R, Schultz LR, Hearshen D, Mikkelsen T.

J Neurooncol. 2010 Feb;96(3):423-31. doi: 10.1007/s11060-009-9981-6. Epub 2009 Oct 27.

PMID:
19859666
11.

Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.

Ellingson BM, Sahebjam S, Kim HJ, Pope WB, Harris RJ, Woodworth DC, Lai A, Nghiemphu PL, Mason WP, Cloughesy TF.

AJNR Am J Neuroradiol. 2014 Apr;35(4):673-9. doi: 10.3174/ajnr.A3748. Epub 2013 Oct 17.

12.

Mechanisms of evasion to antiangiogenic therapy in glioblastoma.

Rose SD, Aghi MK.

Clin Neurosurg. 2010;57:123-8. No abstract available.

PMID:
21280504
13.

Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.

Sunwoo L, Choi SH, Park CK, Kim JW, Yi KS, Lee WJ, Yoon TJ, Song SW, Kim JE, Kim JY, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Chang KH.

J Magn Reson Imaging. 2013 Feb;37(2):351-8. doi: 10.1002/jmri.23838. Epub 2012 Sep 28.

PMID:
23023975
14.

[Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].

Ringelstein A, Turowski B, Gizewski ER, Schroeteler J, Rapp M, Saleh A, Lanzman RS, Mathys C, Sabel M, Mödder U.

Rofo. 2010 Oct;182(10):868-72. doi: 10.1055/s-0029-1245570. Epub 2010 Aug 25. German.

PMID:
20740393
15.

Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.

Fellah S, Girard N, Chinot O, Cozzone PJ, Callot V.

J Clin Oncol. 2011 Apr 10;29(11):e308-11. doi: 10.1200/JCO.2010.32.6082. Epub 2011 Jan 24. No abstract available.

16.

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.

Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T.

J Neurooncol. 2012 Jul;108(3):491-8. doi: 10.1007/s11060-012-0847-y. Epub 2012 Mar 18.

17.

Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.

Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB.

Neuro Oncol. 2011 Oct;13(10):1151-61. doi: 10.1093/neuonc/nor079. Epub 2011 Aug 19.

18.

Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features.

Zhang W, Lin Y, Chen B, Song SW, Jiang T.

Childs Nerv Syst. 2010 Jan;26(1):137-43. doi: 10.1007/s00381-009-0995-3. Epub 2009 Oct 13.

PMID:
19823845
19.

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.

Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D.

Cancer. 2009 Oct 15;115(20):4783-94. doi: 10.1002/cncr.24546.

20.

Bevacizumab antiangiogenic therapy for glioblastoma.

Junck L.

Neurology. 2011 Feb 1;76(5):414-5. doi: 10.1212/WNL.0b013e31820a0d7e. No abstract available.

PMID:
21282587
Items per page

Supplemental Content

Write to the Help Desk